American Oncology Network | Zangmeister Cancer Center

Research site

(Unclaimed)

Location

3100 Plaza Properties Bulevar, Columbus, Ohio, United States of America

Site insights

Top conditions

Top treatments

Sacituzumab

Domvanalimab

Pertuzumab

Disitamab

Vedotin

Leucovorin

Oxaliplatin

Quemliclustat

Trastuzumab

Fluorouracil

Parent organization

This site is a part of American Oncology Network

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 7 total trials

Locations recently updated

A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies (EDGE-Gastric)

The purpose of this study is to evaluate the safety and preliminary clinical activity of treatment combinations with and without chemotherapy in part...

Enrolling

Gastrointestinal Tract Malignancies

Drug: Quemliclustat

Drug: Zimberelimab

Locations recently updated

A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors

This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your b...

Enrolling

HER2 Positive Breast Neoplasms

HER2 Low Breast Neoplasms

Drug: tucatinib

Drug: disitamab vedotin

Locations recently updated

A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)

This study is being done to see if tucatinib works better than placebo when given with other drugs to treat participants with HER2-positive breast ca...

Active, not recruiting

HER2 Positive Breast Cancer

Drug: Pertuzumab

Drug: Trastuzumab

Phase III Study of AK112 for NSCLC Patients

A Randomized, Double-blind, Multi-center, Phase III Clinical Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR...

Enrolling

Non-Squamous Non-small Cell Lung Cancer

Drug: Placebo Injection

Drug: AK112 Injection

Locations recently updated

Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma (XPORT-EC-042)

The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinom...

Enrolling

Endometrial Cancer

Drug: Matching Placebo for selinexor

Drug: Selinexor

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-04)

The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versu...

Enrolling

Triple Negative Breast Cancer

PD-L1 Positive

Drug: Pembrolizumab

Drug: Carboplatin

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-03)

The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of phy...

Enrolling

Triple Negative Breast Cancer

PD-L1 Negative

Drug: Sacituzumab Govitecan-hziy

Drug: Paclitaxel